Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates

Rhea-AI Summary

Moderna (NASDAQ:MRNA) reported Q3 2025 revenue of $1.0B, a GAAP net loss of $200M and GAAP EPS of $(0.51). The company narrowed 2025 revenue guidance to $1.6–$2.0B, improved expected GAAP operating expenses by $0.7B to $5.2–$5.4B, and raised year-end cash projections to $6.5–$7.0B. Cash and investments were $6.6B as of September 30, 2025.

Commercially, Q3 COVID vaccine sales were $971M (U.S. $781M, international $190M); mNEXSPIKE received FDA approval for older adults and certain adults with risk factors and is approved in 40 countries. RSV vaccine mRESVIA generated $2M in Q3 and is approved in 40 countries for 60+ adults. Clinical updates include discontinuation of congenital CMV after a Phase 3 miss, norovirus Phase 3 accrual delays, and multiple late‑stage oncology and rare‑disease milestones on track.

Positive

• COVID vaccine sales of $971M in Q3 2025
• Narrowed 2025 revenue guide to $1.6–$2.0B
• Raised year-end cash guidance to $6.5–$7.0B

Negative

• Total revenue down 45% YoY to $1.0B in Q3 2025
• GAAP net loss of $200M and EPS of $(0.51)
• Discontinued congenital CMV program after Phase 3 failed primary endpoint

Insights

Senior Biotech Analyst

Mixed quarter: lower revenue and a GAAP loss, offset by tighter guidance, meaningful cost cuts, approvals, and mid‑late stage pipeline updates.

Moderna reported third quarter revenue of $1.0 billion, a GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51). COVID vaccine sales drove $971 million of third quarter product revenue with $781 million U.S. and $190 million international sales. Cash, cash equivalents and investments stood at $6.6 billion as of September 30, 2025.

The company narrowed 2025 revenue guidance to $1.6 - $2.0 billion, cut expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion, and raised expected year‑end cash to $6.5 - $7.0 billion. Regulatory progress includes approval of the 2025–2026 mNEXSPIKE formula in 40% of countries noted and FDA approval for specific adult cohorts; mRESVIA sales were $2 million in Q3.

Risks and dependencies are explicit and factual: revenue fell 45% year over year and product sales declined driven by lower vaccination rates and completion of certain government contracts. The company discontinued the congenital CMV program after the Phase 3 study "did not meet its primary efficacy endpoint" and will continue a Phase 2 transplant study, which is a material clinical setback.

Concrete items to watch over the next six months include full‑year revenue trajectory within the new $1.6 - $2.0 billion range, actual year‑end cash within the projected $6.5 - $7.0 billion band, regulatory decisions targeted in 2026 for several markets, and registrational milestones for rare disease candidates where trials are ongoing.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)

Narrows 2025 projected revenue range to $1.6 - $2.0 billion

Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion

Increases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion

CAMBRIDGE, MA / ACCESS Newswire / November 6, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2025.

"We delivered strong commercial and financial performance in the third quarter, supported by COVID vaccine sales following the successful launch of mNEXSPIKE and a significant improvement in expected 2025 operating expenses from our ongoing cost-reduction initiatives," said Stéphane Bancel, Chief Executive Officer of Moderna. "We remain highly focused on operational excellence and financial discipline to advance our pipeline and expand the reach of our commercial portfolio. We look forward to sharing further updates on our business and pipeline at our annual Analyst Day on November 20."

Recent progress includes:

Commercial Updates

COVID-19: The Company reported $971 million in COVID vaccine sales in the third quarter of 2025, which includes $781 million of U.S. sales and $190 million of international sales. The Company has received approval in 40 countries of its 2025-2026 formula for Spikevax®. Moderna has also received U.S. Food and Drug Administration (FDA) approval of its 2025-2026 formula for mNEXSPIKE®, the Company's new COVID vaccine in all adults aged 65 and older, as well as individuals aged 12-64 years with at least one underlying risk factor. mNEXSPIKE is also approved in Canada and the Company has filed and is targeting 2026 approvals in Australia, the EU, Japan and Taiwan.

RSV: The Company reported $2 million in mRESVIA® sales in the third quarter of 2025. mRESVIA, the Company's vaccine for the prevention of lower respiratory tract disease (LRTD) caused by RSV, is approved for all adults aged 60 years and older in 40 countries. It is also approved in 31 of those countries for individuals 18-59 years of age who are at increased risk for disease.

Third Quarter 2025 Financial Results

Revenue: Total revenue for the third quarter of 2025 was $1.0 billion, a 45% decrease from $1.9 billion in the same period in 2024. The decline was primarily driven by a $847 million, or 47%, decrease in net product sales, mainly due to lower COVID vaccine sales. In the U.S., the decrease reflected reduced vaccination rates year over year. The third quarter of 2024 also included an approximately $140 million positive adjustment related to prior-period sales provision estimates, which did not recur in 2025. During the quarter, the Company initiated commercial sales in the U.S. of mNEXSPIKE, as part of the 2025-2026 respiratory virus season.Outside the U.S., revenue decreased primarily due to the completion of certain government contracts and the timing of deliveries.

Cost of Sales: Cost of sales for the third quarter of 2025 was $207 million, which included third-party royalties of $43 million and inventory write-downs of $67 million. Cost of sales decreased 60% compared to the same period in 2024, primarily reflecting lower inventory write-downs and reduced unutilized manufacturing capacity, as well as lower sales volume. As a percentage of net product sales, cost of sales was 21% compared to 28% in the third quarter of 2024. The improvement was mainly driven by productivity gains and efficiencies across manufacturing operations despite lower volumes.

Research and Development Expenses: Research and development expenses for the third quarter of 2025 were $801 million, a 30% decrease compared to the same period in 2024. The reduction was primarily driven by continued investment prioritization and efficiency gains in the execution of clinical trials. Last year's results also included an expense related to the purchase of a priority review voucher.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for the third quarter of 2025 were $268 million, a 5% decrease compared to the same period in 2024. The decline was primarily driven by reductions in consulting and external services across multiple functions, as well as lower digital and facility-related costs, reflecting the Company's continued cost discipline and ongoing efforts to streamline operations.

Income Taxes: Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.

Net Income (Loss): Net loss was $(200) million for the third quarter of 2025, compared to net income of $13 million for the third quarter of 2024.

Earnings (Loss) Per Share: Loss per share was $(0.51) for the third quarter of 2025, compared to earnings per share of $0.03 for the third quarter of 2024.

Cash Position: Cash, cash equivalents and investments as of September 30, 2025, were $6.6 billion, compared to $7.5 billion as of June 30, 2025. The decrease during the quarter was primarily driven by seasonal impacts on working capital.

2025 Financial Framework

Revenue: The Company narrowed its 2025 projected revenue range from $1.5 to $2.2 billion to $1.6 to $2.0 billion, reflecting third quarter results and expectations for the remainder of the year.

Cost of Sales: Cost of sales for 2025 is expected to be approximately $0.8 to $0.9 billion, lowered from $1.2 billion.

Research and Development Expenses: Research and development expenses for 2025 are anticipated to be $3.3 to $3.4 billion, lowered from previous expectations of $3.6 to $3.8 billion.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2025 are projected to be approximately $1.1 billion.

Income Taxes: The Company continues to expect its full-year tax expense to be negligible.

Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.3 billion.

Cash and Investments: Year-end cash and investments for 2025 are projected to be $6.5 to $7 billion, increased from previous expectations of approximately $6 billion.

Recent Progress and Upcoming Late-Stage Pipeline Milestones

Respiratory vaccines:

• Seasonal flu vaccine: In October 2025, Moderna presented Phase 3 efficacy and safety data for its seasonal flu vaccine (mRNA-1010) at IDWeek 2025, and Phase 3 relative vaccine efficacy in a high-risk subset of patients at The European Scientific Working Group on Influenza (ESWI) Conference 2025. The Company expects to complete submissions for approval of mRNA-1010 in the U.S., Canada, Australia and Europe by January 2026.

• Seasonal flu + COVID vaccine: The Company presented Phase 3 immunogenicity subanalyses for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 years and older at ESWI 2025. The Company expects to refile with Health Canada in 2025 and is awaiting further guidance from U.S. FDA on refiling. Currently, the Company's mRNA-1083 filing is under review with the European Medicines Agency (EMA).

Latent and other vaccines:

• Norovirus vaccine: Moderna's ongoing Phase 3 safety and efficacy study of its trivalent vaccine against norovirus (mRNA-1403) has not accrued sufficient cases and will now enroll a second Northern Hemisphere season (2025-2026) for additional case accruals. The timing of the Phase 3 readout will continue to be dependent on case accruals.

• Cytomegalovirus (CMV) vaccine: After announcing that the Phase 3 study of mRNA-1647 did not meet its primary efficacy endpoint, Moderna is discontinuing development of its congenital CMV program. The Company will continue to evaluate mRNA-1647 in an ongoing Phase 2 trial of bone marrow transplant patients.

Oncology therapeutics:

• Intismeran autogene: Moderna continues to make progress on advancing mRNA-4157 in the clinic.In collaboration with Merck, the Phase 3 clinical trial for adjuvant melanoma is fully enrolled. Two non-small cell lung cancer (NSCLC) Phase 3 studies for those with and without prior neoadjuvant treatment are enrolling. Separate randomized Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer are enrolling, a Phase 2 study of first-line treatment for patients with metastatic melanoma is also enrolling, and a randomized Phase 2 study for adjuvant renal cell carcinoma is fully enrolled. Further, Moderna and Merck have launched a new Phase 2 study of first-line treatment for patients with metastatic squamous NSCLC.

• mRNA-4359: The Phase 1/2 study of mRNA-4359, Moderna's investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, is ongoing. Phase 1b data for mRNA-4359 was recently presented at the 2025 European Society for Medical Oncology (ESMO) Congress. The Phase 2 portion of the study, which includes cohorts in first-line metastatic melanoma and first-line metastatic NSCLC, is enrolling patients.

Rare disease therapeutics:

• Propionic acidemia (PA) therapeutic: The Company recently presented final results from the Part 1 dose-escalation cohorts of its ongoing Phase 1/2 study and cumulative data from ongoing participants in the extension study of its investigational therapeutic for PA (mRNA-3927) at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025. In the study, which is designed to evaluate safety and pharmacology in trial participants with PA, mRNA-3927 has been generally well-tolerated to date with no events meeting protocol-defined dose-limiting toxicity criteria. Previously presented results suggest potential decreases in annualized metabolic decompensation event (MDE) frequency compared to pre-treatment, and the majority of patients have elected to continue on the open label extension study. The Company's PA candidate is in a registrational study and target enrollment has been reached.

• Methylmalonic acidemia (MMA) therapeutic: Moderna recently shared interim data from the Phase 1/2 study of its investigational therapeutic for MMA (mRNA-3705) at ICIEM 2025. mRNA-3705 has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, and the FDA and Moderna have agreed on the pivotal study design. The Company expects to start a registrational study in 2026.

Moderna Corporate Updates

• The Company opened its state-of-the-art manufacturing and R&D facility in the UK, which is now licensed by the Medicines and Healthcare products Regulatory Agency (MHRA)

• Moderna announced the first made-in-Canada mRNA vaccines were delivered to Canadian provinces and territories

• The Company's manufacturing facility in Australia was recently granted its Good Manufacturing Practice (GMP) license from the Therapeutic Goods Administration (TGA)

Company Accolades

• Moderna was recognized on BioSpace's Best Places to Work in Biopharma ranking of large employers (fifth consecutive year)

• Moderna was ranked as a top employer in the global biopharmaceutical industry by Science on the Science Careers' 2025 Top Employers Survey (eleventh consecutive year)

Key 2025 Investor and Analyst Event Dates

• Analyst Day: November 20

Investor Call and Webcast Information

Moderna will host a live conference call and webcast at 8:00 a.m. ET on November 6, 2025. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website.

• Telephone: https://register-conf.media-server.com/register/BIc5ea89c0e58143c29f38efc11c3bccc4

• Webcast: https://investors.modernatx.com/

The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in millions, except per share data)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024
Revenue:
Net product sales		$	973			$	1,820			$	1,172			$	2,171
Other revenue1			43				42				94				99
Total revenue			1,016				1,862				1,266				2,270
Operating expenses:
Cost of sales			207				514				416				725
Research and development			801				1,137				2,357				3,421
Selling, general and administrative			268				281				710				823
Total operating expenses			1,276				1,932				3,483				4,969
Loss from operations			(260	)			(70	)			(2,217	)			(2,699	)
Interest income			73				103				244				334
Other income (expense), net			-				(12	)			4				(58	)
(Loss) income before income taxes			(187	)			21				(1,969	)			(2,423	)
Provision for income taxes			13				8				27				18
Net (loss) income		$	(200	)		$	13			$	(1,996	)		$	(2,441	)
Net (loss) earnings per share
Basic		$	(0.51	)		$	0.03			$	(5.15	)		$	(6.37	)
Diluted		$	(0.51	)		$	0.03			$	(5.15	)		$	(6.37	)
Weighted average common shares used in calculation of net (loss) earnings per share
Basic			390				385				388				383
Diluted			390				399				388				383

_______

¹Includes grant, collaboration, licensing and royalty, and other miscellaneous revenue.

MODERNA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions)

		September 30,			December 31,
		2025			2024
Assets
Current assets:
Cash and cash equivalents		$	1,132		$	1,927
Investments			3,372			5,098
Accounts receivable, net			1,046			358
Inventory			332			117
Prepaid expenses and other current assets			716			599
Total current assets			6,598			8,099
Investments, non-current			2,143			2,494
Property, plant and equipment, net			2,126			2,196
Right-of-use assets, operating leases			738			759
Other non-current assets			530			594
Total assets		$	12,135		$	14,142
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable		$	267		$	405
Accrued liabilities			1,178			1,427
Deferred revenue			163			153
Other current liabilities			73			221
Total current liabilities			1,681			2,206
Deferred revenue, non-current			157			58
Operating lease liabilities, non-current			660			671
Financing lease liabilities, non-current			26			39
Other non-current liabilities			281			267
Total liabilities			2,805			3,241
Stockholders' equity:
Additional paid-in capital			1,254			866
Accumulated other comprehensive income (loss)			27			(10	)
Retained earnings			8,049			10,045
Total stockholders' equity			9,330			10,901
Total liabilities and stockholders' equity		$	12,135		$	14,142

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in millions)

		Nine Months Ended September 30,
		2025				2024
Operating activities
Net loss		$	(1,996	)		$	(2,441	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			370				325
Depreciation and amortization			148				129
Amortization/accretion of investments			(54	)			(76	)
Loss on equity investments, net			5				43
Other non-cash items			50				6
Changes in assets and liabilities:
Accounts receivable, net			(703	)			(672	)
Prepaid expenses and other assets			(84	)			(147	)
Inventory			(213	)			(208	)
Right-of-use assets, operating leases			28				(63	)
Accounts payable			(114	)			(103	)
Accrued liabilities			(196	)			(415	)
Deferred revenue			108				(177	)
Operating lease liabilities			(15	)			33
Other liabilities			(137	)			(63	)
Net cash used in operating activities			(2,803	)			(3,829	)
Investing activities
Purchases of marketable securities			(4,221	)			(4,641	)
Proceeds from maturities of marketable securities			4,634				4,648
Proceeds from sales of marketable securities			1,744				3,010
Purchases of property, plant and equipment			(153	)			(529	)
Purchase of intangible asset			(10	)			-
Net cash provided by investing activities			1,994				2,488
Financing activities
Proceeds from issuance of common stock through equity plans			19				55
Tax payments related to net share settlements on equity awards			(1	)			-
Changes in financing lease liabilities			(6	)			4
Net cash provided by financing activities			12				59
Effect of changes in exchange rates on cash and cash equivalents			2				1
Net decrease in cash, cash equivalents and restricted cash			(795	)			(1,281	)
Cash, cash equivalents and restricted cash, beginning of year			1,929				2,928
Cash, cash equivalents and restricted cash, end of period		$	1,134			$	1,647

Spikevax®, mRESVIA® and mNEXSPIKE® are registered trademarks of Moderna.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's 2025 financial framework, including its expected revenue range, operating expenses and year-end cash balance; demand for Moderna's products and Moderna's ability to drive future sales growth; Moderna's continued cost discipline; anticipated regulatory filings and potential approvals; and anticipated milestones for Moderna's pipeline programs, including potential near-term catalysts. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

###

Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

FAQ

What were Moderna's Q3 2025 revenue and GAAP EPS (MRNA)?

Moderna reported Q3 2025 revenue of $1.0B and GAAP EPS of $(0.51).

How much did Moderna sell in COVID vaccines in Q3 2025 (MRNA)?

Moderna reported $971M in COVID vaccine sales in Q3 2025 (U.S. $781M, international $190M).

What is Moderna's updated 2025 revenue and cash guidance (MRNA)?

Moderna narrowed 2025 revenue to $1.6–$2.0B and now expects year‑end cash of $6.5–$7.0B.

Did the FDA approve Moderna's mNEXSPIKE vaccine for 2025-2026 (MRNA)?

Yes. mNEXSPIKE received FDA approval for adults 65+ and ages 12–64 with ≥1 risk factor.

What clinical programs showed setbacks in Moderna's Q3 2025 update (MRNA)?

Moderna discontinued its congenital CMV program after the Phase 3 trial did not meet its primary endpoint; norovirus Phase 3 will enroll an additional season for case accruals.

How did Moderna change its 2025 operating expense expectations (MRNA)?

Moderna improved expected 2025 GAAP operating expenses by $0.7B to a range of $5.2–$5.4B.